CD44 and neoplasm: The over-expression of CD44-ECD induced by CRAd-synNotch and ADX730 was clearly observed in immunohistochemical studies (Fig. 6a, b), and CRAd-synNotch exhibited greater anti-tumor efficacy compared to PBS and CRAd-GFP groups in the T24 mouse model (Fig. 6c, d).